AACS Knockout cell line (Jurkat, Clone E6-1)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

AACS (acetoacetyl-CoA synthetase) encodes an enzyme predicted to catalyze the formation of acetoacetyl-CoA from acetoacetate. AACS participates in cytosolic acetoacetate utilization and is predicted to contribute to metabolic regulation, including positive regulation of insulin secretion. It is therefore relevant to studies of ketone body metabolism and cellular metabolic signaling.

The Jurkat, Clone E6-1 cell line was established from the peripheral blood of a 14-year-old male patient and is a derivative of the Jurkat T-lymphocytic cell line. This clone was generated from Jurkat E6-1 cells through gamma irradiation and complement-mediated selection using anti-CD45 antibodies. It exhibits markedly reduced CD45 expression (5–8% of the parental line), resulting in impaired signal transduction through the T-cell receptor (TcR) complex and the accessory molecule CD2. The cells can produce interleukin-2 (IL-2) following stimulation with calcium ionophore and phorbol ester but show defective IL-2 production after TcR or CD2 activation. This cell line is used as a model for studying T-cell signaling pathways and immune regulation.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.